Stockscreener 앱 받기
13.50
1.75%
-0.24
시간 외 거래:
13.42
-0.08
-0.59%
Viatris Inc 주식(VTRS)의 최신 뉴스
Viatris sets revenue growth targets through 2030 - Investing.com
Viatris : VTRS Investor Event Presentation FINAL (1) - marketscreener.com
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 - PR Newswire
Class Action Filed Against Viatris Inc. (VTRS) Seeking Recovery for InvestorsContact Levi & Korsinsky - The National Law Review
What are analysts saying about Viatris Inc (VTRS) stock? - MSN
Antiretroviral Therapy Market Critical Analysis with Expert Opinion| Gilead Sciences, Viatris, AbbVie - openPR.com
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
What Are Analysts Saying About Viatris Inc (VTRS) Stock? - Insider Monkey
Henrietta Lacks family settles lawsuit against Viatris over cell use - WBFF
Henrietta Lacks family settles lawsuit against Viatris over use of her cells - WJLA
Assessing Viatris (VTRS) Valuation After Mixed Short And Long Term Share Price Moves - Yahoo Finance
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
UBS and BofA Lift Price Targets on Viatris (VTRS) - Insider Monkey
Assessing Viatris (VTRS) Valuation After Recent Share Price Pullback - simplywall.st
Viatris sells Biocon Biologics stake for $815 million in cash and equity deal - MSN
Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research - Reuters
Viatris' Mylan Drops Claims Disputing Novo's Patent-Infringement Suit - marketscreener.com
Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst - TipRanks
Novo, Mylan Seek Judgment on Key Wegovy Patent Before Trial - Bloomberg Law News
Viatris resolves case over use of woman’s cancer cells (VTRS) - Seeking Alpha
GoodRx (GDRX) Partners with Viatris for Major Medication Discoun - GuruFocus
GoodRx offers up to 85% discount on Viatris drugs (GDRX) - Seeking Alpha
Viatris Collaborates With GoodRx for Discounts of Up to 85% on Medications - marketscreener.com
Lipitor and Viagra discounts: GoodRx deal cuts brand drugs to $0–$4 - Stock Titan
Viatris Stock Analysis: Strong 6-Month Gains vs. Poor 5-Year FundamentalsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Trading Systems Reacting to (VTRS) Volatility - Stock Traders Daily
Propranolol Market Overall Study Report 2026-2033 | Teva - openPR.com
Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Viatris (VTRS) CCO granted RSUs, settles prior units and tax withholdings - Stock Titan
Viatris (VTRS) CFO adds 86,017 RSUs and withholds shares for taxes - Stock Titan
Viatris (VTRS) director adds 26K shares via RSU vesting and grant - Stock Titan
Viatris (VTRS) executive Enrietti exercises RSUs, withholds shares for taxes - Stock Titan
Viatris (VTRS) director Mark W. Parrish reports RSU vesting and new equity award - Stock Titan
Viatris (VTRS) executive settles RSUs, receives new 56,727-unit award - Stock Titan
Viatris (VTRS) CEO boosts equity stake with RSU vesting and new award - Stock Titan
[Form 4] Viatris Inc Insider Trading Activity - Stock Titan
VTRS SEC FilingsViatris Inc Ord Shs 10-K, 10-Q, 8-K Forms - Stock Titan
Viatris (VTRS) director Kilts exercises RSUs and receives new stock grant - Stock Titan
Viatris (VTRS) director settles RSUs into shares and receives 15,890-unit grant - Stock Titan
Viatris (VTRS) director exercises RSUs and receives new stock award - Stock Titan
Viatris (VTRS) director acquires shares and new RSUs via awards - Stock Titan
Viatris (VTRS) director reports 684 common shares via trusts - Stock Titan
Viatris (VTRS): Should You Buy, Sell, or Hold After Q4 Results? - Bitget
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Viatris Inc.: - marketscreener.com
Viatris Inc. (VTRS) provides updates on four recent regulatory milestones - MSN
Viatris Eyes Specialty Shift As FDA Reviews MR-141 Presbyopia Drug - Yahoo Finance
Viatris tops forecasts as earnings and revenue beat expectations - MSN
Goldman Sachs Adjusts Price Target on Viatris to $14 From $13, Maintains Neutral Rating - marketscreener.com
FDA Review Of MR-141 Puts Viatris Ophthalmic Growth Story In Focus - Sahm
Better Value & Growth: LLY, JNJ Top Viatris Stock - Trefis
Viatris (VTRS) officer nets stock from RSU and PRSU vesting - Stock Titan
Ex-Dividend Reminder: Alphabet, Constellation Energy and Viatris - Nasdaq
Viatris Stock Hits Day Low of $15.14 Amid Price Pressure - Markets Mojo
Viatris, Inc. Hits New 52-Week High at USD 16.46 - Markets Mojo
Viatris (VTRS) CFO logs RSU vesting, tax share withholding in Form 4 - Stock Titan
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Nasdaq
Viatris Unit Can't Ax Patent For Anemia Drug Evrenzo - Law360
2.39%
0.77%
자본화:
|
볼륨(24시간):